PMID- 27720274
OWN - NLM
STAT- MEDLINE
DCOM- 20170427
LR  - 20240426
IS  - 1097-6787 (Electronic)
IS  - 0190-9622 (Print)
IS  - 0190-9622 (Linking)
VI  - 76
IP  - 2
DP  - 2017 Feb
TI  - Tumor necrosis factor-alpha inhibitor-induced psoriasis: Systematic review of 
      clinical features, histopathological findings, and management experience.
PG  - 334-341
LID - S0190-9622(16)30631-4 [pii]
LID - 10.1016/j.jaad.2016.08.012 [doi]
AB  - BACKGROUND: Tumor necrosis factor-alpha (TNF-alpha) inhibitors have been reported to 
      induce new-onset psoriasis. OBJECTIVE: To better define the demographic, clinical 
      features, and treatment approach of TNF-alpha inhibitor-induced psoriasis. METHODS: 
      Systematic review of published cases of TNF-alpha inhibitor-induced psoriasis. 
      RESULTS: We identified 88 articles with 216 cases of new-onset TNF-alpha 
      inhibitor-induced psoriasis. The mean age at psoriasis onset was 38.5 years. The 
      most common underlying diseases were Crohn disease (40.7%) and rheumatoid 
      arthritis (37.0%). Patients underwent TNF-alpha therapy for an average of 14.0 months 
      before psoriasis onset with 69.9% of patients experiencing onset within the first 
      year. The majority of patients received skin-directed therapy, though patients 
      who discontinued TNF therapy had the greatest resolution of symptoms (47.7%) 
      compared with those who switched to a different TNF agent (36.7%) or continued 
      therapy (32.9%). LIMITATIONS: Retrospective review that relies on case reports 
      and series. CONCLUSION: While TNF-alpha inhibitor cessation may result in resolution 
      of induced psoriasis, lesions may persist. Decisions regarding treatment should 
      be weighed against the treatability of TNF-alpha inhibitor-induced psoriasis, the 
      severity of the background rheumatologic or gastrointestinal disease, and 
      possible loss of efficacy with cessation followed by retreatment. Skin-directed 
      therapy is a reasonable initial strategy except in severe cases.
CI  - Copyright (c) 2016 American Academy of Dermatology, Inc. Published by Elsevier Inc. 
      All rights reserved.
FAU - Brown, Gabrielle
AU  - Brown G
AD  - Department of Dermatology, University of California, San Francisco, California.
FAU - Wang, Eva
AU  - Wang E
AD  - Department of Dermatology, University of California, San Francisco, California.
FAU - Leon, Argentina
AU  - Leon A
AD  - Department of Dermatology, University of California, San Francisco, California.
FAU - Huynh, Monica
AU  - Huynh M
AD  - Department of Dermatology, University of California, San Francisco, California.
FAU - Wehner, Mackenzie
AU  - Wehner M
AD  - Department of Dermatology, University of California, San Francisco, California.
FAU - Matro, Rebecca
AU  - Matro R
AD  - Department of Gastroenterology, University of California, San Francisco, 
      California.
FAU - Linos, Eleni
AU  - Linos E
AD  - Department of Dermatology, University of California, San Francisco, California.
FAU - Liao, Wilson
AU  - Liao W
AD  - Department of Dermatology, University of California, San Francisco, California.
FAU - Haemel, Anna
AU  - Haemel A
AD  - Department of Dermatology, University of California, San Francisco, California. 
      Electronic address: Anna.Haemel@ucsf.edu.
LA  - eng
GR  - K08 AR057763/AR/NIAMS NIH HHS/United States
GR  - K08 CA155035/CA/NCI NIH HHS/United States
GR  - KL2 TR000143/TR/NCATS NIH HHS/United States
GR  - R01 AR065174/AR/NIAMS NIH HHS/United States
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20161005
PL  - United States
TA  - J Am Acad Dermatol
JT  - Journal of the American Academy of Dermatology
JID - 7907132
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Child
MH  - Drug Eruptions/diagnosis/*etiology/therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Psoriasis/*chemically induced/diagnosis/therapy
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors
MH  - Young Adult
PMC - PMC11042689
MID - NIHMS821456
OTO - NOTNLM
OT  - adalimumab
OT  - adverse event
OT  - certolizumab
OT  - etanercept
OT  - golimumab
OT  - infliximab
OT  - medication side effect
OT  - psoriasis
OT  - tumor necrosis factor-alpha inhibitor
OT  - tumor necrosis factor-alpha-induced psoriasis
COIS- Conflict of Interest Disclosure: The authors do not report any conflicts of 
      interest.
EDAT- 2016/10/11 06:00
MHDA- 2017/04/28 06:00
PMCR- 2024/04/24
CRDT- 2016/10/11 06:00
PHST- 2015/10/29 00:00 [received]
PHST- 2016/08/02 00:00 [revised]
PHST- 2016/08/04 00:00 [accepted]
PHST- 2016/10/11 06:00 [pubmed]
PHST- 2017/04/28 06:00 [medline]
PHST- 2016/10/11 06:00 [entrez]
PHST- 2024/04/24 00:00 [pmc-release]
AID - S0190-9622(16)30631-4 [pii]
AID - 10.1016/j.jaad.2016.08.012 [doi]
PST - ppublish
SO  - J Am Acad Dermatol. 2017 Feb;76(2):334-341. doi: 10.1016/j.jaad.2016.08.012. Epub 
      2016 Oct 5.